JP2001506671A - 癌、関節炎および網膜症の治療用抗脈管形成薬 - Google Patents
癌、関節炎および網膜症の治療用抗脈管形成薬Info
- Publication number
- JP2001506671A JP2001506671A JP54076598A JP54076598A JP2001506671A JP 2001506671 A JP2001506671 A JP 2001506671A JP 54076598 A JP54076598 A JP 54076598A JP 54076598 A JP54076598 A JP 54076598A JP 2001506671 A JP2001506671 A JP 2001506671A
- Authority
- JP
- Japan
- Prior art keywords
- arg
- ile
- gly
- val
- thr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. T-Gly-Val-D-Ile-Thr-Arg-Ile-U、 V-Gly-D-Val-Ile-D-Thr-D-Arg-D-Ile-W、 X-D-Arg-D-Ile-D-Arg-D-Thr-Ile-D-Val-YNおよび Z-Gly-Val-Ile-Thr-Arg-Ile-U より成る群の中から選択されるペプチドまたは製薬上許容可能なその塩。ただし 、 Tは存在しないか、またはN−保護基および12個までのアミノ酸残基を含み、 場合によりN−保護基を末端にもつポリペプチドの中から選択され、 UはArgおよびArg−NR1R2(ここで、R1およびR2はそれぞれ独立して 水素および炭素原子1〜4個のアルキルの中から選択される)の中から選択され 、 Vは存在しないか、またはN−保護基であり、 WはD−ArgおよびD−Arg−NR1R2の中から選択され、 Xは存在しないか、またはN−保護基であり、 YはGlyおよびGly−NR1R2の中から選択され、 Zは1〜12個のアミノ酸残基であり、場合によりN−保護基を末端にもつ(こ こで、少なくとも1個のアミノ酸残基はD−アミノ酸残基である)。 2. 式 T-Gly-Val-D-Ile-Thr-Arg-Ile-U を有する、請求項1に記載のペプチドまたは製薬上許容可能なその塩。 3. UがArgおよびArg−NHCH2CH3の中から選択される、請求項2 に記載のペプチドまたは製薬上許容可能なその塩。 4. Tが存在しない、請求項2に記載のペプチドまたは製薬上許容可能なその 塩。 5. Tがアセチルである、請求項2に記載のペプチドまたは製薬上許容可能な その塩。 6. Tが12個までのアミノ酸残基をもち、場合によりアセチルでキャッピン グされているペプチドである、請求項2に記載のペプチドまたは製薬上許容可能 なその塩。 7. TがGly−Asp−であり、場合によりアセチルを末端にもつ、請求項 6に記載のペプチドまたは製薬上許容可能な その塩。 8. Gly-Val-D-Ile-Thr-Arg-Ile-Arg、 Gly-Val-D-IIe-Thr-Arg-Ile-Arg-NH2、 Gly-Val-D-Ile-Thr-Arg-Ile-Arg-NHCH2CH3、 Ac-Gly-Val-D-Ile-Thr-Arg-Ile-Arg、 Ac-Gly-Val-D-Ile-Thr-Arg-Ile-Arg-NH2、 Ac-Gly-Val-D-Ile-Thr-Arg-Ile-Arg-NHCH2CH3、 Tyr-Gly-Val-D-Ile-Thr-Arg-Ile-Arg、 Tyr-Gly-Val-D-Ile-Thr-Arg-Ile-Arg-NH2、 Tyr-Gly-Val-D-Ile-Thr-Arg-Ile-Arg-NHCH2CH3、 Ac-Tyr-Gly-Val-D-Ile-Thr-Arg-Ile-Arg、 Ac-Tyr-Gly-Val-D-Ile-Thr-Arg-Ile-Arg-NH2、 Ac-Tyr-Gly-Val-D-Ile-Thr-Arg-Ile-Arg-NHCH2CH3、 D-Tyr-Gly-Val-D-Ile-Thr-Arg-Ile-Arg、 D-Tyr-Gly-Val-D-Ile-Thr-Arg-Ile-Arg-NH2、 D-Tyr-Gly-Val-D-Ile-Thr-Arg-Ile-Arg-NHCH2CH3、 Ac-D-Tyr-Gly-Val-D-Ile-Thr-Arg-Ile-Arg、 Ac-D-Tyr-Gly-Val-D-Ile-Thr-Arg-Ile-Arg-NH2、 Ac-D-Tyr-Gly-Val-D-Ile-Thr-Arg-Ile-Arg-NHCH2CH3、 Gly-Asp-Gly-Val-D-Ile-Thr-Arg-Ile-Arg、 Gly-Asp-Gly-Val-D-Ile-Thr-Arg-Ile-Arg-NH2、 Gly-Asp-Gly-Val-D-Ile-Thr-Arg-Ile-Arg-NHCH2CH3、 Ac-Gly-Asp-Gly-Val-D-Ile-Thr-Arg-Ile-Arg、 Ac-Gly-Asp-Gly-Val-D-Ile-Thr-Arg-Ile-Arg-NH2、 Ac-Gly-Asp-Gly-Val-D-Ile-Thr-Arg-Ile-Arg-NHCH2CH3、 Ser-Pro-Trp-Ser-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-D-Ile-Thr-Arg-Il e-Arg、 Ser-Pro-Trp-Ser-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-D-Ile-Thr-Arg-Il e-Arg-NH2、 Ser-Pro-Trp-Ser-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-D-Ile-Thr-Arg-Il e-Arg-NHCH2CH3、 Ac-Ser-Pro-Trp-Ser-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-D-Ile-Thr-Arg -Ile-Arg、 Ac-Ser-Pro-Trp-Ser-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-D-Ile-Thr-Arg -Ile-Arg-NH2、および Ac-Ser-Pro-Trp-Ser-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-D-Ile-Thr-Arg -Ile-Arg-NHCH2CH3 より成る群の中から選択される、請求項2に記載のペプチドま たは製薬上許容可能なその塩。 9. 式 V-Gly-D-Val-Ile-D-Thr-D-Arg-D-Ile-W を有する、請求項1に記載のペプチドまたは製薬上許容可能なその塩。 10. Gly-D-Val-Ile-D-Thr-D-Arg-D-Ile-D-Arg、 Gly-D-Val-Ile-D-Thr-D-Arg-D-Ile-D-Arg-NH2、 Gly-D-Val-Ile-D-Thr-D-Arg-D-Ile-D-Arg-NHCH2CH3、 Ac-Gly-D-Val-Ile-D-Thr-D-Arg-D-Ile-D-Arg、 Ac-Gly-D-Val-Ile-D-Thr-D-Arg-D-Ile-D-Arg-NH2、および Ac-Gly-D-Val-Ile-D-Thr-D-Arg-D-Ile-D-Arg-NHCH2CH3 より成る群の中から選択される、請求項9に記載のペプチドまたは製薬上許容可 能なその塩 11. 式 X-D-Arg-D-Ile-D-Arg-D-Thr-Ile-D-Val-Y を有する、請求項1に記載のペプチドまたは製薬上許容可能なその塩。 12. D-Arg-D-Ile-D-Arg-D-Thr-Ile-D-Val-Gly、 D-Arg-D-Ile-D-Arg-D-Thr-Ile-D-Val-Gly-NH2、 D-Arg-D-Ile-D-Arg-D-Thr-Ile-D-Val-Gly-NHCH2CH3、 Ac-D-Arg-D-Ile-D-Arg-D-Thr-Ile-D-Val-Gly、 Ac-D-Arg-D-Ile-D-Arg-D-Thr-Ile-D-Val-Gly-NH2、および Ac-D-Arg-D-Ile-D-Arg-D-Thr-Ile-D-Val-Gly-NHCH2CH3 より成る群の中から選択される、請求項11に記載のペプチドまたは製薬上許容 可能なその塩。 13. 製薬上許容可能な担体と共に請求項1記載のペプチドを含む、抗脈管形 成療法が必要な患者の治療用組成物。 14. 抗脈管形成療法が必要な患者に請求項1記載のペプチドを治療上有効な 量で投与することからなる患者の治療法。 15. 製薬上許容可能な担体と共に請求項1記載のペプチドを含む、癌、関節 炎、乾癬、感染または手術に関連する目の脈管形成、黄斑変性および糖尿病性網 膜症より成る群の中から選択される病気の治療用組成物。 16. 請求項1記載のペプチドを治療上有効な量で患者に投与することからな る、癌、関節炎、乾癬、感染または手術に関連する目の脈管形成、黄斑変性およ び糖尿病性網膜症より成る群の中から選択される病気の治療法。 17. Ser-Pro-Trp-Ser-D-Ser-Ala-Ser-Val-Thr-Ala-Gly- Asp-Gly-Val-D-Ile-Thr-Arg-Ile-Arg、 Ser-Pro-Trp-Ser-D-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-D-Ile-Thr-Arg- Ile-Arg-NH2、 Ser-Pro-Trp-Ser-D-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-D-Ile-Thr-Arg- Ile-Arg-NHCH2CH3、 Ac-Ser-Pro-Trp-Ser-D-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-D-Ile-Thr-A rg-Ile-Arg、 Ac-Ser-Pro-Trp-Ser-D-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-D-Ile-Thr-A rg-Ile-Arg-NH2、および Ac-Ser-Pro-Trp-Ser-D-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-D-Ile-Thr-A rg-Ile-Arg-NHCH2CH3 より成る群の中から選択される、請求項2に記載のペプチドまたは製薬上許容可 能なその塩。 18. 式 Z-Gly-Val-Ile-Thr-Arg-Ile-U を有する、請求項1に記載のペプチドまたは製薬上許容可能なその塩。 19. UがArg、Arg−NH2およびArg−NHCH2CH3の中から選 択され、Zが場合によりN−保護基を末端に もつ、請求項18に記載のペプチドまたは製薬上許容可能なその塩。 20. Ser-Pro-Trp-Ser-D-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-Ile-Th r-Arg-Ile-Arg、 Ser-Pro-Trp-Ser-D-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-Ile-Thr-Arg-Il e-Arg-NH2、 Ser-Pro-Trp-Ser-D-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-Ile-Thr-Arg-Il e-Arg-NHCH2CH3、 Ac-Ser-Pro-Trp-Ser-D-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-Ile-Thr-Arg -Ile-Arg、 Ac-Ser-Pro-Trp-Ser-D-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-Ile-Thr-Arg -Ile-Arg-NH2、 Ac-Ser-Pro-Trp-Ser-D-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-Ile-Thr-Arg -Ile-Arg-NHCH2CH3、 Ser-Pro-Trp-D-Ser-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-Ile-Thr-Arg-Il e-Arg、 Ser-Pro-Trp-D-Ser-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-Ile-Thr-Arg-Il e-Arg-NH2、 Ser-Pro-Trp-D-Ser-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly- Val-Ile-Thr-Arg-Ile-Arg-NHCH2CH3、 Ac-Ser-Pro-Trp-D-Ser-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-Ile-Thr-Arg -Ile-Arg、 Ac-Ser-Pro-Trp-D-Ser-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-Ile-Thr-Arg -Ile-Arg-NH2、および Ac-Ser-Pro-Trp-D-Ser-Ser-Ala-Ser-Val-Thr-Ala-Gly-Asp-Gly-Val-Ile-Thr-Arg -Ile-Arg-NHCH2CH3 より成る群の中から選択される、請求項18に記載のペプチドまたは製薬上許容 可能なその塩。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82066797A | 1997-03-17 | 1997-03-17 | |
US08/820,667 | 1997-03-17 | ||
PCT/US1998/005327 WO1998041542A1 (en) | 1997-03-17 | 1998-03-16 | Antiangiogenic drug to treat cancer, arthritis and retinopathy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008164055A Division JP2009001576A (ja) | 1997-03-17 | 2008-06-24 | 癌、関節炎および網膜症の治療用抗脈管形成薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001506671A true JP2001506671A (ja) | 2001-05-22 |
JP4254972B2 JP4254972B2 (ja) | 2009-04-15 |
Family
ID=25231427
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54076598A Expired - Lifetime JP4254972B2 (ja) | 1997-03-17 | 1998-03-16 | 癌、関節炎および網膜症の治療用抗脈管形成薬 |
JP2008164055A Pending JP2009001576A (ja) | 1997-03-17 | 2008-06-24 | 癌、関節炎および網膜症の治療用抗脈管形成薬 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008164055A Pending JP2009001576A (ja) | 1997-03-17 | 2008-06-24 | 癌、関節炎および網膜症の治療用抗脈管形成薬 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0918795B1 (ja) |
JP (2) | JP4254972B2 (ja) |
AT (1) | ATE280781T1 (ja) |
CA (1) | CA2255661C (ja) |
DE (1) | DE69827223T2 (ja) |
DK (1) | DK0918795T3 (ja) |
ES (1) | ES2231973T3 (ja) |
PT (1) | PT918795E (ja) |
WO (1) | WO1998041542A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6716963B1 (en) | 1998-05-22 | 2004-04-06 | Abbott Laboratories | Peptide antiangiogenic drugs |
HUP0102579A3 (en) * | 1998-05-22 | 2002-02-28 | Abbott Lab | Peptide antiangiogenic drugs, pharmaceutical compositions comprising thereof and their use |
US6774211B1 (en) | 1998-05-22 | 2004-08-10 | Abbott Laboratories | Peptide antiangiogenic drugs |
CO5261544A1 (es) * | 1999-11-22 | 2003-03-31 | Abbott Lab | Peptidos n-alquilados que tienen actividad antiangiogenica |
DK1232183T3 (da) * | 1999-11-22 | 2006-05-29 | Abbott Lab | Peptider, som har antiangiogen aktivitet |
US6777535B1 (en) | 1999-11-22 | 2004-08-17 | Abbott Laboratories | N-alkylated peptides having antiangiogenic activity |
US6753408B1 (en) | 1999-11-22 | 2004-06-22 | Fortuna Haviv | Peptides having antiangiogenic activity |
US20020183242A1 (en) * | 2001-04-11 | 2002-12-05 | Jack Henkin | Peptide antiangiogenic drugs |
US20030119746A1 (en) * | 2001-10-31 | 2003-06-26 | Fortuna Haviv | Hepta-and octapeptides having antiangiogenic activity |
CN1314705C (zh) * | 2005-06-03 | 2007-05-09 | 中国药科大学 | 高效抑制血管生成多肽及其制备方法和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5200397A (en) * | 1990-02-22 | 1993-04-06 | W. R. Grace & Co.-Conn. | Use of peptide analogs of thrombospondin for the inhibition of angiogenic activity |
WO1993016716A1 (en) * | 1992-02-24 | 1993-09-02 | Northwestern University | Method and composition for inhibiting angiogenesis |
AU697624B2 (en) * | 1993-08-13 | 1998-10-15 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods and compositions for stimulating and inhibiting TGF-beta activity |
-
1998
- 1998-03-16 DE DE69827223T patent/DE69827223T2/de not_active Expired - Lifetime
- 1998-03-16 PT PT98911778T patent/PT918795E/pt unknown
- 1998-03-16 WO PCT/US1998/005327 patent/WO1998041542A1/en active IP Right Grant
- 1998-03-16 DK DK98911778T patent/DK0918795T3/da active
- 1998-03-16 ES ES98911778T patent/ES2231973T3/es not_active Expired - Lifetime
- 1998-03-16 EP EP98911778A patent/EP0918795B1/en not_active Expired - Lifetime
- 1998-03-16 JP JP54076598A patent/JP4254972B2/ja not_active Expired - Lifetime
- 1998-03-16 CA CA002255661A patent/CA2255661C/en not_active Expired - Lifetime
- 1998-03-16 AT AT98911778T patent/ATE280781T1/de active
-
2008
- 2008-06-24 JP JP2008164055A patent/JP2009001576A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2255661C (en) | 2004-08-10 |
ES2231973T3 (es) | 2005-05-16 |
ATE280781T1 (de) | 2004-11-15 |
DE69827223T2 (de) | 2006-02-02 |
PT918795E (pt) | 2005-02-28 |
EP0918795B1 (en) | 2004-10-27 |
CA2255661A1 (en) | 1998-09-24 |
DE69827223D1 (de) | 2004-12-02 |
JP4254972B2 (ja) | 2009-04-15 |
JP2009001576A (ja) | 2009-01-08 |
DK0918795T3 (da) | 2005-03-14 |
WO1998041542A1 (en) | 1998-09-24 |
EP0918795A1 (en) | 1999-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5932545A (en) | Antiangiogenic drug to treat cancer, arthritis and retinopathy | |
JP3795906B2 (ja) | 血管新生作用を有するペプチド医薬 | |
JP2009001576A (ja) | 癌、関節炎および網膜症の治療用抗脈管形成薬 | |
JP2764019B2 (ja) | 免疫グロブリンeのためのリセプターに対するモノクローナル抗体 | |
JP2002502235A (ja) | 新規な抗血管形成ペプチド、それをコードするポリヌクレオチド、および血管形成を阻害する方法 | |
JP2005272480A (ja) | トロンボスポンジン−様活性を有するペプチド及びその治療のための使用 | |
US5677182A (en) | Cleavage site blocking antibody to prohormone proteins and uses thereof | |
US10905750B2 (en) | GRP78 antagonist that block binding of receptor tyrosine kinase orphan receptors as immunotherapy anticancer agents | |
JP2004244411A (ja) | ガレクチン9含有医薬 | |
JPH0859700A (ja) | uPARのドメイン2+3のuPA結合部位および抗体 | |
US6774211B1 (en) | Peptide antiangiogenic drugs | |
JP2005517628A (ja) | Mmp−2内の配列に基づいた化合物を使用する、血管形成および腫瘍増殖を阻害するための新規方法並びに組成物 | |
JP2005507864A (ja) | 抗血管新生活性を有するペプチド | |
US20050124548A1 (en) | Peptide antiangiogenic drugs | |
JP3594318B2 (ja) | 抗ヒトスカベンジャーレセプター抗体 | |
JPH10508761A (ja) | 新規pka結合タンパク質及びその使用 | |
MXPA98009612A (en) | Antiangiogenic drug to treat cancer, arthritis and retinopathy | |
WO1989001947A1 (en) | Protein derived from living body | |
WO2020000063A1 (en) | Rheumatoid arthritis treatment | |
JP2003171400A (ja) | 活性型カスパーゼ−14特異的抗体及びその作成方法 | |
JP2004329040A (ja) | ポリセラーゼ−i及びその利用 | |
JPH08333393A (ja) | リポタンパク(a)の診断アッセイおよびそれに用いるペプチド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050128 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071225 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080318 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080428 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080624 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080812 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20080804 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080901 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090106 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090122 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120206 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130206 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130206 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140206 Year of fee payment: 5 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |